As of April 18, 2025, Pfizer Inc. (NYSE: PFE) shares were trading at approximately $31.20, reflecting a 2.4% gain over the past week. However, the stock remains down 9% year-to-date, with analysts citing a challenging transition period for the company's commercial strategy. Despite this, ABRYSVO's expanded use is expected to contribute meaningfully to revenue in the latter half of 2025 and beyond.